MedTrace Logo

OLGA and OLGIM Stage System for Gastric Cancer

NCT03380052 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2900

Last updated 2023-04-13

No results posted yet for this study

Summary

To validate OLGA and OLGIM staging system with serum pepsinogen for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.

Conditions

  • Stomach Neoplasms
  • Atrophic Gastritis
  • Intestinal Metaplasia

Sponsors & Collaborators

  • National Clinical Research Coordination Center, Seoul, Korea

    collaborator OTHER_GOV

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Officials Officials, Officials · Seoul National University Bundang Hospital

Eligibility

Min Age
25 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2021-01-31
Completion
2022-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03380052 on ClinicalTrials.gov